Navigation Links
MiddleBrook Pharmaceuticals Reports Third Quarter 2008 Financial Results
Date:11/13/2008

nvolve risks and uncertainties. In some cases, forward-looking statements are identified by words such as "believe," "anticipate," "expect," "intend," "plan," "potential," "estimate," "will," "may," "predict," "should," "could," "would" and similar expressions. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this announcement. All of these forward-looking statements are based on information available to us at this time. Actual results could differ from those projected in these forward-looking statements as a result of many factors, including those identified in the sections titled "Risk Factors," in our Registration Statement on Form S-3 as filed with the Securities and Exchange Commission on October 17, 2008, and in our "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in our Annual Report on Form 10-K for the year ended Dec. 31, 2007 and in similar disclosures made by us from time to time in our other filings with the Securities and Exchange Commission. We undertake no obligation to update forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our filings with the Securities and Exchange Commission. MiddleBrook, MiddleBrook Pharmaceuticals (stylized), MiddleBrook Pharmaceuticals, Inc., Pulsys, Moxatag and Keflex are our trademarks and have been registered in the U.S. Patent and Trademark Office or are the subject of pending U.S. trademark applications. Each of the other trademarks, tradenames or services marks appearing in this document belongs to its respective holder.

MiddleBrook Pharmaceuticals, Inc.

Consolidated Statements of Income

(Amounts in thousands, except per share amounts)

For the Three Months For t
'/>"/>

SOURCE MiddleBrook Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. MiddleBrook Pharmaceuticals Raises Up to $10 Million from Deerfield Management
2. MiddleBrook Pharmaceuticals Reports Third Quarter 2007 Results
3. MiddleBrook Pharmaceuticals to Raise $21 Million Through Private Placement of Common Equity
4. MiddleBrook Pharmaceuticals Engages Morgan Stanley in Its Strategic Process
5. MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results
6. MiddleBrook Pharmaceuticals Reports Second Quarter 2008 Results
7. MiddleBrook to Webcast Management Presentation at the 10th Annual Rodman & Renshaw Healthcare Conference
8. MiddleBrook Pharmaceuticals Schedules Conference Call and Webcast for Third Quarter 2008 Financial Results
9. MiddleBrook Pharmaceuticals Retains National Account Firm VCG & Associates
10. MiddleBrook Pharmaceuticals Announces Orange Book Listing of Moxatag(TM) Patents
11. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... ... June 30, 2015 , ... Experts estimate that up to 80% ... pain can range from a dull, constant ache (chronic) to a sudden sharp pain ... steroid injections, selective nerve root blocks and rhizotomy treatment, OPTIMAL Pain & Regenerative ...
(Date:6/30/2015)... Las Vegas, NV (PRWEB) , ... June 30, ... ... has recently returned to the U.S. after a 5-day tour in India. ... that are currently collaborating with Trivedi Master Wellness™ and Transformational Leader/Internationally ...
(Date:6/30/2015)... CT (PRWEB) , ... June 30, 2015 , ... ... on Wednesday, June 24, 2015 amidst bright skies and inspirational words. , ... the cherished processional walk from the Glenholme building to the school’s Center for ...
(Date:6/30/2015)... ... June 30, 2015 , ... Healthy and productive interpersonal ... outcomes. According to Dr. Theo Wubbels (Professor of Education, Admissions Dean, Utrecht ... to show “all kinds of behavior when the situation asks for it.” ...
(Date:6/30/2015)... ... June 30, 2015 , ... Scott Purdy, the spokesperson ... to Provider XO. Scott Purdy stated that the XO stands for eXtra Operability (XO) ... automate the workflow processes of the Revenue Cycle. , Provider XO, based in ...
Breaking Medicine News(10 mins):Health News:OPTIMAL Pain & Regenerative Medicine Brings Innovative Back Pain Management Options Including PRP Injections and Stem Cell-like Therapies to Dallas/Ft. Worth Metroplex 2Health News:OPTIMAL Pain & Regenerative Medicine Brings Innovative Back Pain Management Options Including PRP Injections and Stem Cell-like Therapies to Dallas/Ft. Worth Metroplex 3Health News:Trivedi Global Inc. CEO Visits India to Finalize Science Projects to Create Anti-Aging, Overall Health and Probiotic Products with Help of a Multi-Billion Dollar Company 2Health News:Trivedi Global Inc. CEO Visits India to Finalize Science Projects to Create Anti-Aging, Overall Health and Probiotic Products with Help of a Multi-Billion Dollar Company 3Health News:The Glenholme School Graduates Its Class of 2015 2Health News:The Glenholme School Graduates Its Class of 2015 3Health News:The Glenholme School Graduates Its Class of 2015 4Health News:Lessons On Leadership - Top 12 Global Teacher Bloggers Reveal the Best Strategies for Building Positive Leadership in Global Classrooms 2Health News:Dephinitive Systems Is Getting a New Name 2
... HealthDay Reporter , MONDAY, Jan. 23 (HealthDay News) -- Since ... questioned the safety of medical procedures used to terminate pregnancy. ... abortion is safer than carrying a baby to term. ... delivery is 8.8 deaths per 100,000, while the risk of ...
... world media, researchers, academics including several from Simon Fraser ... the Vancouver Convention Centre Feb. 16-20. , Simon Fraser University,s ... of a bell announcing the 2012 AAAS (American Association ... Aquarium yesterday. , "The AAAS conference is a must for ...
... MRI helps surgeons make more informed decisions about nerve-sparing ... new study published online in the journal Radiology ... most common cancer diagnosed in American men, according to ... prostatectomy, or removal of the prostate, is a common ...
... Jan. 24, 2012) For men diagnosed ... drug dutasteride ("Avodart") delays disease progression and initiating active ... a three-year international clinical trial led by Dr. Neil ... Network (UHN). The findings are published online ...
... Wakeling is adding to the arsenal of increasingly sophisticated ... viewing muscle activation details that have never been seen ... movement in people and animals, Wakeling has developed a ... proprietary data-processing software to scan and capture 3D maps ...
... By Randy Dotinga HealthDay Reporter , MONDAY, Jan. ... be bad for you, a new study finds that parts of ... with others. It,s not clear how this effect of stress ... system -- which cause inflammation in the body -- have been ...
Cached Medicine News:Health News:Abortion Safer for Women Than Childbirth, Study Claims 2Health News:Abortion Safer for Women Than Childbirth, Study Claims 3Health News:SFU hits hot buttons at 2012 AAAS conference 2Health News:SFU hits hot buttons at 2012 AAAS conference 3Health News:Preoperative MRI may reduce risk of nerve damage in prostate cancer surgeries 2Health News:Prostate cancer study proves drug delays disease progression 2Health News:Study Shows How Stress Triggers Immune System 2Health News:Study Shows How Stress Triggers Immune System 3
(Date:6/29/2015)... VILLAGE, Nev. , June 29, 2015  PDL ... it has entered into a credit agreement with CareView ... with up to $40 million of secured debt financing. ... industry focused on patient care monitoring. Under ... to $40 million of debt financing in two tranches ...
(Date:6/29/2015)... NESS ZIONA, Israel , ... Ltd. (Nasdaq: BVXV, TASE: BVXV) today announced positive preliminary ... M-001, BiondVax,s candidate for a universal influenza vaccine. In ... the ages of 50 to 65, followed by an ... 3 weeks later. M-001 was found to be safe ...
(Date:6/29/2015)... , June 29, 2015 DURECT ... James E. Brown , President and CEO, ... Conference on Wednesday, July 8 at 11:45 a.m. ... Le Parker Meridien Hotel in New York City.  ... may request a one-on-one meeting through the conference ...
Breaking Medicine Technology:PDL BioPharma Announces $40 Million Financing Transaction with CareView Communications 2PDL BioPharma Announces $40 Million Financing Transaction with CareView Communications 3PDL BioPharma Announces $40 Million Financing Transaction with CareView Communications 4BiondVax Presents BVX-006 Preliminary Phase II Results: the Universal Flu Vaccine at Higher Doses is Safe and Improves Immunogenicity in Older Adults 2BiondVax Presents BVX-006 Preliminary Phase II Results: the Universal Flu Vaccine at Higher Doses is Safe and Improves Immunogenicity in Older Adults 3DURECT to Present at the Cantor Fitzgerald Healthcare Conference 2
... risk of,stroke by 34% in patient with atrial fibrillation or ... adequately treated by antithrombotic ... a,post-hoc analysis of the data from the ATHENA study were ... Society of Cardiology,congress 2008, in Munich, Germany. Previous results from ...
... in Subjects with ALS, RICHMOND, Calif., Sept. 3 ... that it has opened a Phase,2 clinical trial (SB-509-801) ... progressive, degenerative motor-neuron disease for which there,are limited treatment ... an injectable formulation of a plasmid,encoding a zinc finger ...
Cached Medicine Technology:Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 2Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 3Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 4Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 5Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 2Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 3Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 4Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 5
Inquire...
... three styles. Each style has multiple sizes. ... popular style. Pectoral Implants are available non-sterile ... individually, not in pairs. Both styles are ... for a specific side and are directional. ...
... In vivo results may be affected by the ... scar tissue can impact the desired augment-ation 1 ... from patient to patient. Implant dimensions can be ... surgical scissors. All dimensions in centimeters. This device ...
... IQmark family elevates your ECG and Spirometry capabilities ... and efficient patient care. The IQmark Diagnostic PDA ... clinics and medical centers as well as for ... conjunction with the IQmark Digital ECG PDA and ...
Medicine Products: